CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (NASDAQ: CERS) announced today that the Belgian Red Cross Flanders (RC-F) has signed a five-year agreement to purchase the INTERCEPT Blood System for platelets. RC-F is one of two major Red Cross blood services in Belgium, and supplies approximately 37,000 platelet components to the northern, or Flemish, region of Belgium.
“We believe that INTERCEPT was selected for implementation in Flanders based on the product's accumulated hemovigilance and clinical data, which was thoroughly reviewed by the Belgian Red Cross Flanders as part of the technology’s validation,” said Caspar Hogeboom, president of Cerus Europe and EEMEA. “We are extremely pleased and proud to supply INTERCEPT to all blood centers across Belgium, contributing toward the country's goal of universal pathogen inactivation for platelets and plasma.”
The Belgian Red Cross Flanders’ decision to proceed with the INTERCEPT Blood System is a key step toward making pathogen inactivation the standard of care in Europe. With approximately 65,000 platelet units produced annually, Belgium joins countries such as Switzerland, Iceland and Kuwait in making pathogen inactivated blood components generally available for all patients.
Cerus Corporation is a biomedical products company focused in the field of blood safety. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. In the United States, Cerus is seeking regulatory approval of the INTERCEPT Blood System for plasma and platelets. The INTERCEPT red blood cell system is in clinical development.
See http://www.cerus.com for more information.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.
Lainie Corten, 925-288-6319
Sr Director, Global Marketing & Investor Relations
Source: Cerus Corporation